Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-DCD polyclonal antibody is a rabbit-derived polyclonal antibody targeting dermcidin (DCD), a protein localized at 12q13.1 that functions as a tumor growth and cell survival factor in certain cancers. Dermcidin is typically produced by eccrine sweat glands and processed into antimicrobial peptides, but it has been identified as a candidate oncogene in melanoma and other skin cancers. In preclinical models, the administration of this antibody has demonstrated the ability to delay tumor growth in human melanoma G361 xenografts, suggesting that neutralizing DCD can inhibit oncogenic stimuli and reduce cellular resistance to cytotoxic agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-DCD polyclonal antibody.